Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ablaze Pharmaceuticals logo — Leading the Innovative Targeted Radiotherapy Landscape in Ch...

Ablaze Pharmaceuticals

Leading the Innovative Targeted Radiotherapy Landscape in China.

Founded 2021 China Shanghai, China 10 employees Series A Total: $75.00M Biotechnology, Pharmaceutical

General Information

Company Name Ablaze Pharmaceuticals
Founded Year 2021
Location China Shanghai, China +4
Employees 10
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Social

Get notified when Ablaze Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Ablaze Pharmaceuticals

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company founded in 2011 with a mission to revolutionize the targeted radiotherapy landscape in China. The company has garnered attention for its partnership with RayzeBio, Inc., a leading radiopharmaceutical firm based in San Diego, CA. This strategic alliance has granted Ablaze exclusive rights for development and commercialization of a range of RayzeBio’s products in the greater China region. With a focus on the burgeoning market for targeted radiopharmaceutical therapies (TRT), Ablaze is poised to emerge as a pioneering force in this sector in China by collaborating with key partners both domestically and internationally. The latest milestone for Ablaze Pharmaceuticals was the $75.00M Series A investment on 29 November 2021, with a consortium of prominent investors including Vivo Capital, AdvanTech Capital, Nan Fung Life Sciences, Samsara BioCapital, VenBio Partners, Pivotal bioVenture Partners China, Venrock Healthcare Capital Partners, and RAYZ Investments. Ablaze Pharmaceuticals' commitment to advancing innovative radiopharmaceutical therapies in China positions it as a compelling prospect for investment in the biotechnology and pharmaceutical industries. For more information, please visit www.ablazepharma.com.

Taxonomy: Pharmaceuticals, Clinical-stage, Radiopharmaceuticals, Cancer treatment, Targeted therapy, Drug development, Partnership, Radiopharmaceutical company, Cross-border product development, Business networking, China market, Strategic partnerships, Healthcare innovation, Oncology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 8
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		29 Nov 2021

Ablaze Pharmaceuticals Alternatives & Competitors

Ablaze Pharmaceuticals vs
Full-Life Technologies
Full-Life Technologies Belgium

A Fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China.

Series B
64 employees
Biopharma, Health Care
Ablaze Pharmaceuticals vs
TRT
TRT Singapore

Providing cost-effective solutions for IBM, HP, Dell, Cisco EMC, Netapp & more servers, storage & ne...

1944 employees
Hardware, IT
Ablaze Pharmaceuticals vs
NorthStar Medical Radioisotopes, LLC
NorthStar Medical Radioisotopes, LLC United States

Our Mission: Providing Patients Global Access to Game-Changing Radiopharmaceuticals

Grant
284 employees
Health Care, Health and Wellness
Also compare with: Ablaze Pharmaceuticals vs RayzeBio RayzeBio

FAQ About Ablaze Pharmaceuticals

Leading the Innovative Targeted Radiotherapy Landscape in China.
Ablaze Pharmaceuticals was founded in 2021.
Ablaze Pharmaceuticals is headquartered in Shanghai, China.
Ablaze Pharmaceuticals operates in the following industries: Biotechnology, Pharmaceutical.
Ablaze Pharmaceuticals has approximately 10 employees.
Ablaze Pharmaceuticals has completed 1 funding round, raising a total of $75.00M. The latest funding stage is Series A.
Top alternatives and competitors to Ablaze Pharmaceuticals include Full-Life Technologies, TRT, NorthStar Medical Radioisotopes, LLC, Archeus Technologies, Ablaze Energy. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ablaze Pharmaceuticals and Full-Life Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ablaze Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy